Life Sciences Insight

Cytiva to Invest $500 Million over 5 Years for Global Expansion

Research & Biopharmaceutical Manufacturing | Cytiva, formerly GE Healthcare  Life Sciences

Cytiva, formally GE Life Sciences, was purchased by Danaher Corporation earlier this year. Under the new parent company, the organization is poised for a sizable expansion. The planned investment is roughly $500 Million which will dispersed across 5 years with a focus on expanding the company’s manufacturing capacity.

The COVID-19 pandemic has increased short-term demand, but the biotherapeutics industry has been forecasted to double over the next 30 years. Cytiva’s long-term strategy is increase their capacity on a global scale to align with the projected industry growth.

Talent Acquisition

Cytiva is planning to hire 1,000 individuals in the United States, Austria, China, Singapore, Sweden, & Switzerland which will be either in manufacturing or distribution hubs. In particular, Cytiva is planning on hiring 200 people in the Boston, MA area and will build a new 80,000 square foot facility based in Shrewsbury.

Upgrades to Facilities

The Shrewsbury facility will be one of their planned expansions among other across the globe. Additionally, there will be upgrades made to manufacturing lines, 24/7 shift patterns, as well as increased automation capabilities. The upgrades will provide the company with a greater manufacturing capacity across their product lines.

About Cytiva

Cytiva is a global life sciences leader with over 7,000 associates across 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency, and capacity to research and manufacturing workflows, enabling the development, manufacture, and delivery of transformative medicines to patients.